Mines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher Scientific Inc. to develop and commercialize Mines Biomed's next-generation colorectal cancer screening product. This partnership will leverage Thermo Fisher's advanced technologies to enhance Mines Biomed's mRNA-based assays aimed at early cancer detection, including both colorectal cancer and precancerous lesions. The collaboration, involving Mines Biomed's laboratory in Mainz, Germany, aims to accelerate the availability of innovative cancer screening tests globally. Key figures like Guido Bechler, CEO of Mines Biomed, and Peter Jacobs, Director at Thermo Fisher, expressed optimism about the partnership's potential to significantly advance colorectal cancer diagnostics.
Category
🗞
NewsTranscript
00:00Mines Biomed, a molecular genetics diagnostic company specializing in the early detection
00:06of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc.
00:10NYSE, TMO, through its subsidiary Life Technologies Corporation. Thermo Fisher is
00:15a world leader in supplying life sciences solutions and services with annual revenue
00:20of over 40 billion dollars, marking a major milestone for Mines Biomed.
00:24The collaboration agreement will enable Mines Biomed and Thermo Fisher to jointly develop
00:28and potentially commercialize Mines Biomed's next-generation colorectal cancer screening
00:32product. The collaboration will harness Thermo Fisher's powerful technologies,
00:36instrumentation, and information translation systems to enable Mines Biomed to develop
00:40the proprietary assays for its mRNA-based next-generation CRC screening tests,
00:44which are redefining standards in early cancer detection.
00:47Mines Biomed's flagship non-invasive test not only targets the early detection of colorectal cancer,
00:52but also focuses on precancerous lesions, particularly advanced adenomas,
00:56demonstrating significant clinical success in both U.S. and European trials.
01:00The collaboration will leverage combined capabilities to deliver testing solutions
01:04being developed at Mines Biomed's laboratories in Mainz, Germany.
01:07Guido Baechler, CEO of Mines Biomed, said,
01:10This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a
01:14home-collection colorectal screening tool with highly effective detection of adenomas.
01:19Our product development will be greatly enhanced by Thermo Fisher's knowledge
01:22and scalable, class-leading technologies, providing both partners with a means to
01:26accelerate the availability of an innovative new test for colorectal cancer screening around the world.
01:30Peter Jacobs, Director, EMEA Clinical Business Development, Thermo Fisher Scientific, said,
01:36We are excited at the prospect of working with Mines Biomed on their next-generation screening
01:40test and are confident that together we will be able to achieve rapid progress
01:44and deliver innovative new assays for the global clinical marketplace.